Indian Journal of Pharmacy and Pharmacology最新文献

{"title":"Safety and efficacy of nadifloxacin versus clindamycin observed in a tertiary care teaching hospital of Deccan Plateau","authors":"S Kumar, Tamilisetti Vidya Sagar","doi":"10.18231/j.ijpp.2023.007","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.007","url":null,"abstract":"Acne vulgaris is characterised by excess sebum production and inflammatory reaction in sebaceous glands. As propionibacterium is involved in aggravation of acne, antimicrobials like nadifloxacin and clindamycin were found to be effective in treatment.Comparison of nadifloxacin with clindamycin in terms of inflammatory and non-inflammatory lesion count and global improvement rating, when given in combination with benzoyl peroxide in patients in acne vulgarisNadifloxacin 1%, benzoyl peroxide 2.5% and clindamycin 1% were used as topical treatment option. Study cohort was randomly divided into two groups: Nadifloxacin group and Clindamycin group. All subjects who were included in the study were instructed to apply a thin layer of medication over acne lesions; benzoyl peroxide 2.5% gel once daily at bedtime and clindamycin 1% gel or Nadifloxacin 1% gel twice daily. Efficacy is analysed by comparing changes in total, inflammatory and non-inflammatory lesion counts, In addition, global improvement was rated by patients using a six-point scale (worsening, no improvement, slight improvement, moderate improvement, good improvement, clearance) at end of treatment.There is progressive decline in number of inflammatory and non-inflammatory lesions in both groups. Analysis of lesion counts not showed any significant difference in between two groups. In global improvement rating scale, more number of patients using nadifloxacin with benzoyl peroxide reported good improvement compared to patients using Clindamycin with benzoyl peroxide. No patient in any group reported worsening of lesions. None of patients in study groups reported clearance. Two adverse events were reported during study, they were, burning sensation and dryness. There was no significant difference in incidence of adverse events in both treatment groups.Topical Nadifloxacin, a new fluoroquinolone is effective, tolerable and safe for mild or moderate facial acne. Its clinical effectiveness is equivalent to clindamycin when used as add-on therapy to benzoyl peroxide.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"15 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89449201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Synthesis of zinc ferrite nanoparticles and evaluation of their antifungal properties at different temperatures","authors":"J. Jacob, Jyothish Babu, Nisha S Thulasi, Keerthi Mohandas","doi":"10.18231/j.ijpp.2023.008","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.008","url":null,"abstract":"Zinc ferrite nanoparticles have been synthesized by the co-precipitation method where Polyethylene Glycol act as the capping agent. The sample structure and morphology of the product were analysed by powder XRD, FTIR, U-V visible spectroscopy and scanning electron microscope (FE-SEM). The prepared NPs were annealed at varying temperatures such as 500℃, 600℃ and 700℃. The XRD data confirms the presence of nanosized ZnFeO particles and the X-ray density of the sample and their particle size increases linearly along with the increase in annealing temperature, but the lattice parameter changes inversely. The FTIR data also provide information about nanosized zinc ferrite particles. The surface characteristics of ZnFeO were observed by FESEM. The anti-fungal properties of zinc ferrite nanoparticles were also evaluated.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"615 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81998929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent insights into the role of antifibrotic drugs in the management of idiopathic pulmonary fibrosis (IPF)","authors":"R. Chakraverty, Jyotirmoy Bondyopadhyay","doi":"10.18231/j.ijpp.2023.002","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.002","url":null,"abstract":"Idiopathic aspiratory fibrosis (IPF) is the most well-known sort of idiopathic interstitial pneumonia (IIP). IIPs are precipitously shappening (idiopathic) diffuse parenchymal lung illnesses. IPF is characterized as a precipitouly happening (idiopathic) explicit type of persistent fibrosing interstitial pneumonia restricted to the lung and related with an example of Usual Interstitial Pneumonia (UIP) on imaging or histology. Pleasant rules for the analysis of Interstitial Lung Disease (ILD), preceding thought for against fibrotic treatment, specify that the conclusion of ILD has been made by a multidisciplinary group (MDT).","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"190 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73167665","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Herbal medicated gummies: A flange approach in management of depression and anxiety","authors":"Payaam Vohra, Sunanda R. Patil, Walia Khan","doi":"10.18231/j.ijpp.2023.005","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.005","url":null,"abstract":"According to WHO Depression is a common internal complaint. Encyclopedically, it's estimated that 264 million of grown-ups suffer from depression. Depression is a leading cause of disability worldwide and is a major contributor to the overall global burden of complaint. This exploration totally focuses upon formulating a drug for people suffering from depression in a fascinating and fluently respectable way. The condition of depression has worsen post epidemic with increase in number of cases associated with youth. This paper briefly discusses preface of the antidepressant sauces in a sticky form. Flavonoid and associated phytochemicals exerts an antidepressant effect via modulation of central noradrenaline(NA), dopamine(DA), serotonin(5- HT), and γ- amino butyric acid(GABA) neurotransmission. Turmeric specifically, curcumin could be a mainstream depression treatment. A combination of Turmeric, Tulsi and chamomile can prove to be a boon for operation of Depression with minimum side goods. This medicine delivery system provides fresh patient benefits and compliance, offering several advantages over tablets or liquid phrasings in that, the remedial system isn't to be swallowed and this increases patient compliance, especially for elders and pediatrics with swallowing diseases; also, the product can be taken anywhere and at any time as it doesn't bear liquids to prop swallowing. This expression seems to be a promising combination of the sauces for productive operation of depression and anxiety.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"23 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74084172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A review on potential anti-diabetic herbs and polyherbal formulations concept","authors":"J. Kher, Hemangiben Hasmukhbhi Patel","doi":"10.18231/j.ijpp.2023.003","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.003","url":null,"abstract":"Multifactorial diseases, for diabetes develop various complication like hepatic toxicity, retinopathy, neuropathy, nephropathy and immunodeficiency etc. Numerous medicinal herbs have been used for the diabetes mellitus in traditional systems of medicine worldwide as they are a great source of phytochemical constituents and many of them are known to be effective against diabetes. Medicinal herbs with antidiabetic activities are being more desired, to lesser side effect and low cost. The efficacy of antihyperglycemic herbs is achieved by increasing insulin secretion, enhancing glucose uptake, activate GLP and inhibiting glucose production. The antidiabetic herbs contains many phytochemical constituents they single herb use produce mild effect when the combining of two — three herbs which having different chemical constituent and pharmacological action and produce synergistic effect and avoid repeated dose and achieve the efficacies therapeutic effec.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"29 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78677344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A prospective, post-marketing surveillance (PMS) study to monitor the safety of fixed dose combination of Triprolidine Hydrochloride IP 2.5 mg and Phenylephrine Hydrochloride IP 5 mg [Recofast Tablets] for the symptomatic relief in patients with upper respiratory tract infections","authors":"Sachin Madhukar Kadoo, Preksha Pramod Patil","doi":"10.18231/j.ijpp.2023.010","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.010","url":null,"abstract":"Upper Respiratory Tract Infection (URTI) is the most frequent illness in humans. The vast majority of acute upper respiratory tract infections are caused by viruses. These cause a variety of patient diseases including acute bronchitis, common cold, influenza, and respiratory distress syndromes.The study was conducted in patients with upper respiratory tract infections to see if the medication provides symptomatic relief in these conditions. Other conditions like allergic rhinitis and influenza were also included in the study for symptomatic relief.This is an open label, multicentric, active Post Marketing Surveillance (PMS) study with an objective to assess safety of fixed dose combination regarding Recofast tablets (Triprolidine Hydrochloride IP 2.5 mg and Phenylephrine Hydrochloride IP 5 mg) which was evaluated in 150 participants from different geographical regions. And then results were documented. A total of 19 (13%) patients recorded minor adverse event from these regions. Out of 150 patients 95 were male & 55 were female. All the patients were in the range of 18-80 years.No significant adverse events were observed during the course of the study, only 13% patients recorded minor adverse events from all regions. Thus this formulation is completely safe and effective in the management of Upper Respiratory Tract Infections and allergies.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"49 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80355240","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Commentary on cardiovascular safety of DPP4Is: Focus on Alogliptin","authors":"A. Trailokya, A. Zargar, M. Tiwaskar, S. Kale, Amar Shirsat","doi":"10.18231/j.ijpp.2023.013","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.013","url":null,"abstract":"DPP-4 inhibitors are present in the market for almost more than a decade. In Management of T2DM, DPP-4 inhibitors are established therapy option. The precise guidance for the pre- and post-approval and also CV safety of the newer antidiabetic agents was released by the USFDA in 2008. A neutral effect of Pooled safety analyses, as well as retrospective meta-analyses of clinical trials, have consistently demonstrated that DPP-4 inhibitors are not associated with any increase in cardiovascular adverse events, and have even pointed towards a risk reduction. The combination therapy of Alogliptin with other agents like metformin and pioglitazone have been shown to provide better and superior efficacy as compared to individual monotherapy. The hypoglycemic risk is less with Alogliptin. Alogliptin has been shown to be associated with less risk of hepatotoxicity, weight gain, and acute pancreatitis. Alogliptin does not worsen outcomes in patients with a history of heart failure (HF), neither does it increase rate of new hospitalization for heart failure (HF), as per the data from EXAMINE trial.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91159748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term thromboprophylaxis in metallic aortic valve prosthesis using oral nattokinase-A case report","authors":"Dhaval Dalal, Vijaykumar Gawali","doi":"10.18231/j.ijpp.2023.011","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.011","url":null,"abstract":"Oral anticoagulation with a vitamin K antagonist like warfarin is the standard of care for thromboprophylaxis after cardiac valve replacement. However warfarin requires strict monitoring of INR to avoid bleeding.Bleeding is a major concern with warfarin, particularly in those at high risk. Nattokinase is an enzyme obtained from natto, a cheese-like food made of soybeans fermented with Bacillus subtilis, which has been consumed as a traditional food in certain Asian countries for more than 2000 years.Recent research has demonstrated that nattokinase has potent fibrinolytic activity and antithrombotic action. We present a case of a 37-year-old male who had undergone aortic valve replacement using a metallic prosthetic valve for rheumatic heart disease associated severe aortic regurgitation and has been maintained on oral nattokinase therapy for prophylaxis against thromboembolic complications post cardiac wall replacement since the last 12 years.This case highlights the role of oral nattokinase for thromboprophylaxis in valve prosthesis and other prothrombotic states. This case report presents the first documented case where oral nattokinase has been successfully used for long-term thromboprophylaxis in metallic aortic valve prosthesis.: We present a case of a 37-year-old male who had undergone aortic valve replacement using a metallic prosthetic valve for rheumatic heart disease associated severe aortic regurgitation and has been maintained on oral nattokinase therapy for prophylaxis against thromboembolic complications post cardiac wall replacement since the last 12 years.This case highlights the role of oral nattokinase for thromboprophylaxis in valve prosthesis and other prothrombotic states. This case report presents the first documented case where oral nattokinase has been successfully used for long-term thromboprophylaxis in metallic aortic valve prosthesis.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"111 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78959621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Importance of antibiotic therapy in post-surgical patients","authors":"Anitta Pottananikkal, Athira Varghese, Sunitha Sam, V. Chandy","doi":"10.18231/j.ijpp.2023.004","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.004","url":null,"abstract":"Antibiotics are the class of medication that prevent the infections that is caused by bacteria; antibiotics make it difficult to grow or multiply or directly killing them. But the widespread misuse of antibiotics can also lead to serious consequences. In the case of post-operative patients, the empirical antibiotics should be selected based on the site of infection, etiology, and pharmacokinetics of the antibiotics. Therefore, the rational use of empirical antibiotics is based on the increase in the total count and also the spike in temperature. The review focus on the time, duration, rationality, and selection of empirical antibiotics, and antibiotic prescription patterns in different departments and different age groups.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"102 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74757002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fixed dose combinations in India- what a way to go!","authors":"S. Chaudhry","doi":"10.18231/j.ijpp.2023.012","DOIUrl":"https://doi.org/10.18231/j.ijpp.2023.012","url":null,"abstract":"Fixed dose combinations (FDCs) are generally considered desirable options in chronic diseases such as tuberculosis, cardiovascular diseases & diabetes, tropical diseases such as malaria & in HIV and in Cancer. FDCs are useful in chronic conditions especially when multiple disorders often co-exist The advantages of the FDC are basically patients compliance, simple dosage schedule, better efficacy, cheaper shipment & packaging activities. The drawbacks of FDCs are (a) Pharmacodynamic mismatch between the two ingredients, one drug having additive/antagonistic effect leading to reduced efficacy or enhanced side effects, (b) Pharmacokinetic disparity having peak efficacy at different time zone, (c) Chemical non compatibility leading to decreased shelf life, (d) Drug interactions due to common metabolizing pathways, and (e) limitations of dose titration of individual ingredients. As per Rule 122 E of Drugs and Cosmetics Act 1940, the FDCs are considered as New Drugs where the Central Drugs Standard Control Organization (CDSCO), ensures proper clinical data is submitted for the approval into the market. Appendix VI of Schedule Y (Drugs & Cosmetics Rules 1945) mentions the requirements for marketing approval of various types of FDCs.","PeriodicalId":13313,"journal":{"name":"Indian Journal of Pharmacy and Pharmacology","volume":"70 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72955045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}